Cardiologists, lipid specialists, and clinicians managing adults with hypercholesterolemia or established cardiovascular disease will use these source labels to select and dose PCSK9‑pathway therapies; REPATHA has trial‑reported cardiovascular outcome data and well‑characterized LDL‑C percent reductions in the supplied sources ^[5][3]. The available label information supports that REPATHA reduced both LDL‑C (−63% at Week 12) and the risk of the trial primary composite endpoint (HR 0.85) in FOURIER, while PRALUENT and LEQVIO labels document LDL‑lowering indications without directly comparable percent data in the provided excerpts ^[4][1][2][5]. An open clinical question is how the magnitude of LDL‑C lowering with monoclonal anti‑PCSK9 antibodies versus inclisiran translates into comparable long‑term cardiovascular outcomes across similar patient populations?

Q1 What are REPATHA, PRALUENT, and LEQVIO approved for?

REPATHA (evolocumab) is indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and as an adjunct to diet to reduce LDL‑C in adults with primary hyperlipidemia, including heterozygous and homozygous familial forms, and in certain pediatric patients 10 years and older with familial hypercholesterolemia. PRALUENT (alirocumab) is indicated to reduce major adverse cardiovascular events in adults at increased risk and to reduce LDL‑C in adults and pediatric patients with familial hypercholesterolemia. LEQVIO (inclisiran) appears in the supplied FDA label materials, but detailed indication language and dates were not available in the provided source excerpts.

Q2 How do these agents work?

Evolocumab is described in FDA labeling as a human monoclonal IgG2 that binds human PCSK9 and prevents PCSK9‑mediated LDL receptor degradation, increasing LDL receptor availability and lowering LDL‑C. PRALUENT is labeled as a PCSK9 inhibitor; its label describes LDL‑C lowering and cardiovascular risk reduction consistent with PCSK9 pathway inhibition. LEQVIO (inclisiran) is included in the provided FDA AccessData materials, but mechanism‑of‑action detail was not reported in the provided source excerpts for this summary.

Q3 What are the recommended doses in the labels?

REPATHA dosing in adults with established cardiovascular disease or primary hyperlipidemia is either 140 mg subcutaneously every 2 weeks or 420 mg subcutaneously once monthly; specific pediatric and HoFH recommendations are included in the REPATHA label. PRALUENT dosing for adults with hypercholesterolemia typically starts at 75 mg subcutaneously every 2 weeks or 300 mg every 4 weeks, with adjustment options and specific regimens for HeFH and HoFH noted in the PRALUENT label. Dosing information for LEQVIO (inclisiran) was present in the supplied label files but exact dose text was not extractable in the provided source excerpts for this summary. Clinicians should consult current prescribing information for complete dosing guidance.

Q4 What are the side effects to expect?

REPATHA labeling and trial summaries record injection site reactions, nasopharyngitis, upper respiratory tract infection, influenza, back pain, and other events reported more frequently than placebo in trials; specific event rates are tabulated in the prescribing information. PRALUENT labeling lists injection site reactions, influenza, diarrhea, myalgia, muscle spasms, and contusion among adverse reactions observed more frequently than with placebo; myalgia was among events reported in cardiovascular outcome experience. Safety details for LEQVIO (inclisiran) were not reported in the provided source excerpts for this summary.

Clinicians should consult current prescribing information for complete dosing guidance.